Impact of baseline microbiological status on clinical outcomes in generalized aggressive periodontitis patients treated with or without adjunctive amoxicillin and metronidazole: an exploratory analysis from a randomized controlled clinical trial. (11th September 2014)

• Record Type: Journal Article
• Authors: Guerrero, Adrián; Nibali, Luigi; Lambertenghi, Roberta; Ready, Derren; Suvan, Jean; Griffiths, Gareth S.; Wilson, Michael; Tonetti, Maurizio S.
• Is Part Of: Journal of clinical periodontology. Volume 41:Number 11(2014:Nov.)
• Page Start: 1080
• Page End: 1089
• Publication Date: 2014-09-11
• Subjects: Periodontics -- Periodicals; 617.6
• DOI: 10.1111/jcpe.12299
• Languages: English
• ISSNs: 0303-6979

Abstract

<abstract abstract-type="main" id="jcpe12299-abs-0001"> <title>Abstract</title> <sec id="jcpe12299-sec-0001" sec-type="section"> <title>Aim</title> <p>To explore whether subjects harbouring <italic>A. actinomycetemcomitans</italic>, <italic> P. gingivalis</italic> or <italic>T. forsythia</italic> at baseline showed increased clinical benefits with the adjunctive use of systemic amoxicillin and metronidazole (AMX‐MET) during non‐surgical treatment of generalized aggressive periodontitis (GAgP).</p> </sec> <sec id="jcpe12299-sec-0002" sec-type="section"> <title>Material and Methods</title> <p>Forty one subjects were included in this 6‐month randomized placebo‐controlled clinical trial using a 7‐day course of systemic AMX‐MET or placebo as adjuncts to non‐surgical periodontal therapy. Clinical and microbiological parameters were collected at baseline, 2 and 6 months after treatment. Microbiological cultures were processed for pooled subgingival samples and identities of isolates were determined by PCR for <italic>A. actinomycetemcomitans</italic>, <italic> P. gingivalis</italic> and <italic>T. forsythia</italic></p> </sec> <sec id="jcpe12299-sec-0003" sec-type="section"> <title>Results</title> <p>At 6 months, the test treatment resulted in significant additional improvements in the primary outcome variable compared to placebo, and the effect of the adjunctive antimicrobials was not modified by the baseline microbiological status in the primary analysis. However, secondary exploratory subgroup analyses showed improved clinical outcomes in subjects harbouring <italic>A. actinomycetemcomitans</italic> at baseline compared to subjects who did not harbour this pathogen.</p> </sec> <sec id="jcpe12299-sec-0004" sec-type="section"> <title>Conclusions</title> <p>All subjects benefited from the tested adjunctive antimicrobial regimen, although subjects who harboured <italic>A. actinomycetemcomitans</italic> at baseline may show greater clinical benefits. Larger appropriately powered studies are needed to confirm whether adjunctive AMX‐MET is more beneficial for GAgP patients who harbour <italic>A. actinomycetemcomitans, </italic> along with other key periodontal pathogens.</p> </sec> </abstract>